395 related articles for article (PubMed ID: 26709030)
1. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
Torka P; Al Ustwani O; Wetzler M; Wang ES; Griffiths EA
Blood Rev; 2016 May; 30(3):201-11. PubMed ID: 26709030
[TBL] [Abstract][Full Text] [Related]
2. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
[TBL] [Abstract][Full Text] [Related]
3. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide consolidation in APL.
Das M
Lancet Oncol; 2017 Sep; 18(9):e517. PubMed ID: 28803794
[No Abstract] [Full Text] [Related]
7. Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
Wang H; Hao L; Wang X; Li J; Wu Q; Bian S
Int J Hematol; 2010 Jun; 91(5):820-5. PubMed ID: 20461563
[TBL] [Abstract][Full Text] [Related]
8. The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.
Falchi L; Verstovsek S; Ravandi-Kashani F; Kantarjian HM
Cancer; 2016 Apr; 122(8):1160-8. PubMed ID: 26716387
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
10. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lengfelder E; Hofmann WK; Nowak D
Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
[TBL] [Abstract][Full Text] [Related]
11. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
12. Arsenic trioxide in the treatment of haematological malignancies.
Kwong YL
Expert Opin Drug Saf; 2004 Nov; 3(6):589-97. PubMed ID: 15500417
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
Lam MS; Ignoffo RJ
Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
[No Abstract] [Full Text] [Related]
14. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
Liu P; Han ZC
Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
[TBL] [Abstract][Full Text] [Related]
15. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
Slack JL; Waxman S; Tricot G; Tallman MS; Bloomfield CD
Oncologist; 2002; 7 Suppl 1():1-13. PubMed ID: 11961204
[TBL] [Abstract][Full Text] [Related]
16. Insights into the All-trans-Retinoic Acid and Arsenic Trioxide Combination Treatment for Acute Promyelocytic Leukemia: A Meta-Analysis.
Ma H; Yang J
Acta Haematol; 2015; 134(2):101-8. PubMed ID: 25925330
[TBL] [Abstract][Full Text] [Related]
17. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
18. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
[TBL] [Abstract][Full Text] [Related]
19. Ancient remedy performs new tricks.
Mervis J
Science; 1996 Aug; 273(5275):578. PubMed ID: 8701308
[No Abstract] [Full Text] [Related]
20. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
Chou WC; Dang CV
Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]